Back to Authors

Hardacre, Jeffrey M.

Mayo Clinic

Cleveland Clinic

Citations 2

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. Gabriela , Chiaro, Marco Del , Tempero, Margaret A. , Malafa, Mokenge P. , Benson, Al B. , Cardin, Dana B. , Christensen, Jared A. , Czito, Brian G. , Dillhoff, Mary , Donahue, Timothy R. , Hardacre, Jeffrey M., Klute, Kelsey , Ko, Andrew H. , LoConte, Noelle K. , Lowy, Andrew M. , Masood, Ashiq , Moravek, Cassadie, Nakakura, Eric K. , Narang, Amol , Nardo, Lorenzo , Obando, Jorge, Reddy, Sushanth , Reyngold, Marsha , Scaife, Courtney L. , Shen, Jeanne , Truty, Mark J. , Vollmer, Charles M., Wolff, Robert A. , Wolpin, Brian M. , McCullough, Beth, Lubin, Senem, Darlow, Susan, Cardin, Dana B , LoConte, Noelle , Chung, Vincent , Dotan, Efrat , Fountzilas, Christos , Glazer, Evan S. , Hawkins, William G , Kunstman, John W. , Polanco, Patricio Marcelo

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 753-782

10.6004/jnccn.2023.0034 Get It

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.
Laparoscopic and Hand-Assisted Distal Pancreatectomy
Laxa, Bernadette, Cobb, William S., Rosen, Michael J. , Hardacre, Jeffrey M., Mekeel, Kristin L. , Harold, Kristi L., Carbonell, Alfredo M.

The American Surgeon™ | June 17, 2020 | Volume: 74 | Issue: 6 | Pages: 481-487

10.1177/000313480807400605 Get It

With the increased use of CT, discovering incidental pancreatic lesions has become commonplace. Lesions in the distal pancreas lend themselves well to laparoscopic resection. We reviewed our experience with laparoscopic distal pancreatectomy. During the study period, 32 distal pancreatectomies were performed. There were 20 females. Mean patient age was 58.0 years (range, 23–83 years) and mean body mass index was 29.9 kg/m 2 (range, 19.9–44.7 kg/m 2 ). Technique was laparoscopic (25) or hand-assisted (seven) with one conversion in each group. The spleen was preserved in six patients (18.8%). Mean operative time overall was 238 minutes (range, 140–515 minutes); hand-assisted was 222 minutes and laparoscopic was 254 minutes. Estimated blood loss averaged 221 mL (range, 50–1800 mL). Mean tumor size was 2.7 cm (range, 0.6–7 cm). Tumor pathology was serous cystadenoma (10), neuroendocrine tumor (six), mucinous cystic neoplasm (four), intrapapillary mucinous neoplasm (four), adenocarcinoma (three), other (four), and solid pseudopapillary neoplasm (one). Mean length of stay was 5 days (range, 3–11 days). Complications were pancreatic fistula (six), wound infection (two), pulmonary embolism (one), pancreatitis (one), myocardial infarction (one), postoperative bleed from combined laparoscopic bilateral oophorectomy (one), and pancreatic stump staple line bleed requiring reoperation (one). There were no perioperative deaths. All pancreatic fistulas resolved with conservative management.